Press release
Aptinyx Inc. (NASDAQ: APTX) Investor Investigation over potential Wrongdoing
An investigation on behalf of investors in Aptinyx Inc. (NASDAQ: APTX) shares over potential wrongdoing at Aptinyx Inc.
Investors who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Aptinyx Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Evanston, IL based Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx Inc. completed its initial publis offering ("IPO") on June 21, 2018, offering $16.00 per share for net proceeds of $92.2 million. However, since the IPO shares of Aptinyx Inc. (NASDAQ: APTX) declined to as low as $2.96 per share on August 26, 2019.
Those who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aptinyx Inc. (NASDAQ: APTX) Investor Investigation over potential Wrongdoing here
News-ID: 2033814 • Views: …
More Releases from Shareholders Foundation
Lawsuit for Investors in Sonder Holdings Inc. (NASDAQ: SOND) filed in effort to …
An investor, who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND), filed a lawsuit over alleged violations of Federal Securities Laws by Sonder Holdings Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Sonder Holdings Inc. (NASDAQ: SOND) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: SOND investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
Lawsuit filed for Investors in Ocugen, Inc. (NASDAQ: OCGN) in effort to recover …
An investor, who purchased shares of Ocugen, Inc. (NASDAQ: OCGN), filed a lawsuit i over alleged violations of Federal Securities Laws by Ocugen, Inc..
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN) have certain options and for certain investors are short and strict deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Malvern, PA based Ocugen, Inc., a…
Investors who lost money with shares of Evolv Technologies Holdings, Inc. (NASDA …
An investor, who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), filed a lawsuit in the U.S. District Court for the District of Massachusetts over alleged violations of Federal Securities Laws by Evolv Technologies Holdings, Inc. f/k/a NewHold Investment Corp.
Investors who purchased shares of Evolv Technologies Holdings, Inc. (NASDAQ: EVLV) have certain options and for certain investors are short and strict deadlines running. Deadline: May 24, 2024. NASDAQ: EVLV…
Investigation announced for Investors who purchased shares of Comtech Telecommun …
Comtech Telecommunications Corp is under investigation over potential securities laws violations in connection with certain financial statements.
Investors who purchased shares of Comtech Telecommunications Corp. (NASDAQ: CMTL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Comtech Telecommunications Corp. regarding its business, its prospects and its operations were materially false…
More Releases for Aptinyx
Chemotherapy Induced Peripheral Neuropathy Treatment Market Future Challenges An …
QY Research has recently published a new report, titled Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Report, History and Forecast 2017-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chemotherapy Induced Peripheral Neuropathy Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and…
Chemotherapy Induced Peripheral Neuropathy Treatment Market Size, Geography Tren …
Market Insights:
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended. There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs,…
Fibromyalgia Treatment Market Profiling Players (Pfizer, Novartis AG, Allergan, …
Global Fibromyalgia Treatment Market overview:
The report " Fibromyalgia Treatment Market" The quick adoption of advanced Analytics and Visualization and the expand use of outward data sources are the major drivers of the Fibromyalgia Treatment Market. The report high Point, Potential Growth Opportunities in the coming years and covers a review of the Market Drivers, Growth Measure, Competitive Landscape, Market Dynamics, Opposition and other Feature to the Fibromyalgia Treatment Market.
Get a…
Chemotherapy Induced Peripheral Neuropathy Treatment Market Business Opportuniti …
An analysis of Chemotherapy Induced Peripheral Neuropathy Treatment Market has been provided in the latest report launched by UpMarketResearch.com that primarily focuses on the market trends, demand spectrum, and future prospects of this industry over the forecast period. Furthermore, the report provides a detailed statistical overview in terms of trends outlining the geographical opportunities and contributions by prominent industry share contenders.
Click Here To Access PDF Sample Copy @ https://www.upmarketresearch.com/home/requested_sample/51736
Moreover, the…
Investigation announced for Investors in Aptinyx Inc. (NASDAQ: APTX) over possib …
An investigation was announced over potential securities laws violations by Aptinyx Inc. in connection with certain financial statements.
Investors who purchased shares of Aptinyx Inc. (NASDAQ: APTX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by Aptinyx Inc. regarding its business, its prospects and its operations were materially false and…
Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 |by Trends Anal …
MarketResearchNest.com published an Exclusive Research Report on “Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024” that highlights the in-depth market analysis and covers significant data with future prospects of the market.
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle…
